Drug intelligence / Profile preview

SAR447754

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules

Overview

**SAR447754** is an investigational **small-molecule pharmaceutical drug** being developed by **Sanofi** for **atopic dermatitis**. Publicly available evidence identifies it as a distinct Sanofi clinical candidate that entered a **first-in-human Phase 1 trial** in healthy adults and adults with **moderate-to-severe atopic dermatitis** in 2026. The precise molecular target and mechanism of action have not been publicly disclosed in the sources reviewed, so it is best characterized at present as an early-stage immunology/dermatology asset for atopic dermatitis with undisclosed mechanism.

Beyond the preview

Go deeper on SAR447754.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAR447754.

Explore the full profile